This study aims to develop a robust computational model for classifying potential Hepatitis C Virus (HCV) NS5B inhibitors using Quantitative Structure-Activity Relationship (QSAR) analysis. A large number of biological activity data for HCV NS5B was collected from the ChEMBL database, and molecular descriptors were calculated to characterize the compounds. A stacking classifier approach was employed for accurate classification using LightGBM + XGBoost as base models and Random Forest as the meta-classifier. The proposed model demonstrated improved performance compared to individual models, achieving an accuracy of 85.07% on the testing set. We assessed the model reliability through various evaluation procedures, including precision, recall, F1-score, and y-scrambling. The applicability domain was also analyzed to determine the model’s reliability for predicting compounds outside the training set. Overall, the developed model holds promise as a valuable tool in early-stage drug discovery for prioritizing compounds with inhibitory potential against HCV NS5B.
No takes yet. Share an insight, caveat, or question.
Noviandy et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: